Brainstorm Cell Therapeutics Inc.
BCLI
BCLI: Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
moreShow BCLI Financials
Recent trades of BCLI by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by BCLI's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Populations of mesenchymal stem cells that secrete neurotrophic factors Feb. 18, 2020
-
Patent Title: Methods of generating mesenchymal stem cells which secrete neurotrophic factors Aug. 14, 2018
Federal grants, loans, and purchases
Followers on BCLI's company Twitter account
Number of mentions of BCLI in WallStreetBets Daily Discussion
Recent insights relating to BCLI
Recent picks made for BCLI stock on CNBC
ETFs with the largest estimated holdings in BCLI
Flights by private jets registered to BCLI